Martin Lechmann

1.6k total citations
30 papers, 1.1k citations indexed

About

Martin Lechmann is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Hepatology. According to data from OpenAlex, Martin Lechmann has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Radiology, Nuclear Medicine and Imaging, 13 papers in Immunology and 13 papers in Hepatology. Recurrent topics in Martin Lechmann's work include Monoclonal and Polyclonal Antibodies Research (14 papers), Hepatitis C virus research (12 papers) and Protein purification and stability (6 papers). Martin Lechmann is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), Hepatitis C virus research (12 papers) and Protein purification and stability (6 papers). Martin Lechmann collaborates with scholars based in Germany, Switzerland and United States. Martin Lechmann's co-authors include T. Jake Liang, Ulrich Spengler, Tilman Sauerbruch, Kazumoto Murata, G. Jung, Rolf Kaiser, Jujin Satoi, Rainer P. Woitas, John Vergalla and Toshiaki Gunji and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Immunology and Gastroenterology.

In The Last Decade

Martin Lechmann

28 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin Lechmann Germany 15 599 439 308 269 264 30 1.1k
Penelope Mavromara Greece 23 760 1.3× 613 1.4× 219 0.7× 425 1.6× 99 0.4× 68 1.4k
Vicky M.-H. Sung United States 12 1.1k 1.8× 784 1.8× 302 1.0× 300 1.1× 155 0.6× 14 1.6k
Gabrielle Vièyres Germany 20 883 1.5× 663 1.5× 239 0.8× 296 1.1× 229 0.9× 31 1.4k
Koen Vercauteren Belgium 18 493 0.8× 405 0.9× 168 0.5× 287 1.1× 82 0.3× 44 1.0k
Volker Brass Germany 18 1.0k 1.7× 818 1.9× 123 0.4× 337 1.3× 153 0.6× 28 1.5k
Matthew Paulson United States 14 421 0.7× 399 0.9× 273 0.9× 319 1.2× 68 0.3× 18 1.0k
William R. Addison Canada 14 646 1.1× 626 1.4× 203 0.7× 379 1.4× 58 0.2× 24 1.3k
John McLauchlan United Kingdom 19 1.0k 1.7× 1.3k 3.0× 186 0.6× 224 0.8× 74 0.3× 30 1.6k
Muriel Lavie France 16 307 0.5× 285 0.6× 84 0.3× 202 0.8× 123 0.5× 23 769
Rosa Maria Roccasecca United States 8 927 1.5× 735 1.7× 83 0.3× 342 1.3× 315 1.2× 8 1.3k

Countries citing papers authored by Martin Lechmann

Since Specialization
Citations

This map shows the geographic impact of Martin Lechmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Lechmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Lechmann more than expected).

Fields of papers citing papers by Martin Lechmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Lechmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Lechmann. The network helps show where Martin Lechmann may publish in the future.

Co-authorship network of co-authors of Martin Lechmann

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Lechmann. A scholar is included among the top collaborators of Martin Lechmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Lechmann. Martin Lechmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lechmann, Martin, Katharine Bray‐French, Anneliese Schneider, et al.. (2025). Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primates. Journal of Immunotoxicology. 22(1). 2537408–2537408.
2.
Shah, Nirav N., Martin Lechmann, Hardik Mody, et al.. (2024). Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy. Clinical Pharmacology & Therapeutics. 117(1). 34–55. 2 indexed citations
3.
Ducret, Axel, Olivier Rohr, Timothy P. Hickling, et al.. (2024). Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity. Frontiers in Immunology. 15. 1406643–1406643. 3 indexed citations
4.
Dudal, Sherri, Caterina Bissantz, Antonello Caruso, et al.. (2022). Translating pharmacology models effectively to predict therapeutic benefit. Drug Discovery Today. 27(6). 1604–1621. 8 indexed citations
5.
Falck, David, Martin Lechmann, Marco Thomann, et al.. (2022). Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model. mAbs. 14(1). 2145929–2145929. 7 indexed citations
6.
Kim, Michael T., et al.. (2021). In Vivo Reoxidation Kinetics of Free Thiols in Multiple Domains of IgG1 Antibodies in Rats. Journal of Pharmaceutical Sciences. 110(5). 1989–1996. 1 indexed citations
7.
8.
Falck, David, Marco Thomann, Martin Lechmann, et al.. (2020). Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody. mAbs. 13(1). 1865596–1865596. 29 indexed citations
9.
Kronenberg, Sven, Christine M. Schubert, Christian Freichel, et al.. (2017). Comparative assessment of immune complex-mediated hypersensitivity reactions with biotherapeutics in the non-human primate: Critical parameters, safety and lessons for future studies. Regulatory Toxicology and Pharmacology. 88. 125–137. 17 indexed citations
10.
Bauss, Frieder, Martin Lechmann, Ben‐Fillippo Krippendorff, et al.. (2016). Characterization of a re‐engineered, mesothelin‐targetedPseudomonasexotoxin fusion protein for lung cancer therapy. Molecular Oncology. 10(8). 1317–1329. 48 indexed citations
11.
Moebius, Ulrich, et al.. (2006). Efficacy of Oncolytic Herpesvirus NV1020 Can Be Enhanced by Combination with Chemotherapeutics in Colon Carcinoma Cells. Human Gene Therapy. 0(0). 3311231409–3311231409. 6 indexed citations
12.
Moebius, Ulrich, et al.. (2006). Efficacy of Oncolytic Herpesvirus NV1020 Can Be Enhanced by Combination with Chemotherapeutics in Colon Carcinoma Cells. Human Gene Therapy. 17(12). 1241–1253. 33 indexed citations
13.
Lechmann, Martin, Kazumoto Murata, Jujin Satoi, et al.. (2001). Hepatitis C Virus-Like Particles Induce Virus–Specific Humoral and Cellular Immune Responses in Mice. Hepatology. 34(2). 417–423. 83 indexed citations
14.
Lechmann, Martin & T. Jake Liang. (2000). Vaccine Development for Hepatitis C. Seminars in Liver Disease. 20(2). 211–226. 64 indexed citations
15.
Lechmann, Martin, Rainer P. Woitas, Bettina Langhans, et al.. (1999). Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. Journal of Hepatology. 31(6). 971–978. 71 indexed citations
16.
Baumert, Thomas F., John Vergalla, Jujin Satoi, et al.. (1999). Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology. 117(6). 1397–1407. 104 indexed citations
17.
Spengler, U., Ludger Leifeld, I Braunschweiger, et al.. (1997). Anomalous expression of costimulatory molecules B7-1, B7-2 and CD28 in primary biliary cirrhosis. Journal of Hepatology. 26(1). 31–36. 36 indexed citations
18.
Woitas, Rainer P., Martin Lechmann, G. Jung, et al.. (1997). CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. The Journal of Immunology. 159(2). 1012–1018. 103 indexed citations
19.
20.
Spengler, Ulrich, et al.. (1996). Immune responses in hepatitis C virus infection.. PubMed. 24(2 Suppl). 20–5. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Penelope Mavromara Breakdown of academic impact, for papers by Vicky M.-H. Sung Breakdown of academic impact, for papers by Gabrielle Vièyres Breakdown of academic impact, for papers by Koen Vercauteren Breakdown of academic impact, for papers by Volker Brass Breakdown of academic impact, for papers by Matthew Paulson Breakdown of academic impact, for papers by William R. Addison Breakdown of academic impact, for papers by John McLauchlan Breakdown of academic impact, for papers by Muriel Lavie Breakdown of academic impact, for papers by Rosa Maria Roccasecca
Rankless by CCL
2026